SPH-4336
- Generic Name
- SPH-4336
A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
- Target Recruit Count
- 63
- Registration Number
- NCT05944224
- Locations
- 🇨🇳
The First Affiliated Hospital，Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, China
Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Shanghai Pharma Biotherapeutics USA Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT05580588
- Locations
- 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Mayo Clinic Florida, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath